{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:09:01Z","timestamp":1759410541189},"reference-count":37,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.vaccine.2015.04.027","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T18:36:05Z","timestamp":1429641365000},"page":"2800-2807","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: A phase IV, randomized, open-label, controlled study"],"prefix":"10.1016","volume":"33","author":[{"given":"Patricia","family":"Izurieta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong-Heon","family":"Wie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamadou","family":"Dram\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Schuind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.04.027_bib0190","series-title":"Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003\u20132014","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0195","series-title":"FDA approves first adjuvanted vaccine for prevention of H5N1 avian influenza","author":"Food and Drug Administration","year":"2013"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0200","series-title":"H5N1 Influenza Virus Vaccine, manufactured by Sanofi Pasteur, Inc. Questions and Answers","author":"US Food and Drug Administration","year":"2013"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0205","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1016\/j.vaccine.2009.07.102","article-title":"Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults","volume":"27","author":"Chu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0210","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/INF.0b013e3181daf921","article-title":"Immunogenicity and safety of H5N1 A\/Vietnam\/1194\/2004 (clade 1) AS03-adjuvanted pre-pandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study","volume":"29","author":"D\u00edez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0215","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0220","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0225","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0230","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/infdis\/jiu359","article-title":"Heterologous Prime\u2013boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children <3 years of age","volume":"210","author":"Nolan","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0235","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.4161\/21645515.2014.972149","article-title":"Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials","volume":"10","author":"Vaughn","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0240","doi-asserted-by":"crossref","first-page":"e1665","DOI":"10.1371\/journal.pone.0001665","article-title":"Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine","volume":"3","author":"Leroux-Roels","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0245","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2334-14-142","article-title":"Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults","volume":"14","author":"Gillard","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0250","unstructured":"European Medicines Agency. European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003945.pdf\u3009 [accessed 20 November 2014]. in press."},{"key":"10.1016\/j.vaccine.2015.04.027_bib0255","series-title":"Concepts and procedures for laboratory-based influenza surveillance","first-page":"B17","article-title":"Hemagglutination inhibition","author":"Kendal","year":"1982"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0260","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0265","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virusres.2004.02.019","article-title":"Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A\/Duck\/Singapore\/97 vaccine","volume":"103","author":"Stephenson","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0270","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00044011-200222110-00004","article-title":"Ten years of experience with the trivalent split-influenza vaccine, Fluarix\u2122","volume":"22","author":"Hehme","year":"2002","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0275","series-title":"Clinical data needed to support the licensure of pandemic influenza vaccines","author":"US Food and Drug Administration","year":"2007"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0280","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jfma.2011.02.006","article-title":"Safety and immunogenicity of a split-virion AS03A-adjuvanted A\/Indonesia\/05\/2005 (H5N1) vaccine in Taiwanese adults","volume":"111","author":"Yang","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0285","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(06)68656-X","article-title":"Safety and immunogenicity of an inactivated split-virion influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine: phase I randomised trial","volume":"367","author":"Bresson","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0290","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0295","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.vaccine.2008.02.068","article-title":"Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial","volume":"26","author":"Rumke","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0300","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature04795","article-title":"Strategies for mitigating an influenza pandemic","volume":"442","author":"Ferguson","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0305","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1473-3099(08)70232-9","article-title":"Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans","volume":"8","author":"Jennings","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0310","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.vaccine.2014.07.062","article-title":"Immunogenicity and safety of AS03-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years","volume":"33","author":"Godeaux","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0315","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-2659.2012.00349.x","article-title":"An assessment of prime\u2013boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults","volume":"7","author":"Gillard","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0320","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2009.10.017","article-title":"Priming with AS03(A)-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0325","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.vaccine.2008.08.046","article-title":"Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0330","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(09)62026-2","article-title":"Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials","volume":"375","author":"Plennevaux","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0335","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1086\/655830","article-title":"AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age","volume":"51","author":"Roman","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0340","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3201\/eid1806.111631","article-title":"Avian influenza a (H5N1) virus antibodies in poultry cullers, South Korea, 2003\u20132004","volume":"18","author":"Kwon","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0345","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/cid\/cit047","article-title":"Assessment of serosurveys for H5N1","volume":"56","author":"Toner","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0350","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/WNL.0000000000000987","article-title":"Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States","volume":"83","author":"Duffy","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0355","series-title":"Narcolepsy in association with pandemic vaccination; a multi-country European epidemiological investigation","author":"European Centre for Disease Control and Prevention","year":"2012"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0360","doi-asserted-by":"crossref","first-page":"f794","DOI":"10.1136\/bmj.f794","article-title":"Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine: retrospective analysis","volume":"346","author":"Miller","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0365","doi-asserted-by":"crossref","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","article-title":"AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.04.027_bib0370","doi-asserted-by":"crossref","first-page":"e33723","DOI":"10.1371\/journal.pone.0033723","article-title":"Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland","volume":"7","author":"Partinen","year":"2012","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T17:41:11Z","timestamp":1651772471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15004806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":37,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0264410X15004806"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: A phase IV, randomized, open-label, controlled study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}